FINWIRES · TerminalLIVE
FINWIRES

生物燃料最新动态:大豆油有望连续第四个月上涨,棕榈油价格回落

By

-- 周四,芝加哥大豆油期货有望连续第四个月上涨,而马来西亚棕榈油由于出口放缓,部分回吐了上月涨幅。 芝加哥期货交易所(CBOT)5月大豆油合约早盘走势平稳,接近合约高点,报每磅75.32美分。该合约本月有望上涨9.4%,与原油市场的强劲表现相符。 大豆油市场的强劲表现提振了大豆价格,CBOT 5月大豆合约周四有望实现0.7%的月度涨幅。早盘交易中,该合约较前一交易日收盘价下跌0.23%,至每蒲式耳11.79美元。 生物燃料需求的增长以及阿根廷大豆因降雨而延迟收割,支撑了大豆价格,并缓解了市场对供应过剩的担忧。 据Trading Economics的数据显示,阿根廷棕榈油目前的收成进度仅为10%,而往年同期平均进度为60%。 巴西的棕榈油收成已完成90%以上。据价格报告机构MySteel援引行业数据称,4月份巴西棕榈油出口量可能同比增长21.5%,达到1640万吨。 在美国,棕榈油种植速度仍高于五年平均水平,但部分地区的降雨可能会减缓种植进度。 在亚洲,马来西亚棕榈油期货在交易日尾盘回落,月度跌幅约为6%,原因是出口疲软抵消了原油价格上涨和生物燃料需求增长带来的利好。 马来西亚衍生品交易所5月原棕榈油合约下跌0.02%,结算价为每吨4504马来西亚林吉特(1133.94美元)。 6月合约价格小幅下跌0.11%,至每吨4,540令吉。 4月份的下跌部分抵消了上月因美伊冲突爆发而取得的19%的涨幅。 尽管原油价格走强,但MySteel表示,“(棕榈油)市场可能会重新关注现货市场的短期压力。” 基本面疲软继续对价格构成压力,尤其是据货运调查员估计,4月1日至25日期间马来西亚棕榈油出货量环比下降15.7%至16.8%。 季节性低迷过后,市场预期未来几个月产量将有所回升,这也加剧了市场悲观情绪。 与此同时,由于担心化肥成本飙升和可能发生的干旱,全年产量展望显示供应将趋紧。 据路透社报道,印尼棕榈油协会主席埃迪·马托诺警告称,如果厄尔尼诺现象持续发展,且农民在季末推迟施肥,该国棕榈油产量可能下降100万至200万吨。 MySteel表示,“短期内,棕榈油价格预计将在一定范围内波动”,并指出高企的原油价格对棕榈油价格的支撑有限。 在美国,纽约商品交易所(NYMEX)5月交割的乙醇期货价格周三上涨3.27%,至每加仑2.05美元,原因是行业数据显示,每周出口量激增,而产量下降。 美国能源信息署的数据显示,截至4月24日当周,乙醇出口量几乎翻了一番,达到每日17万桶,而前一周为每日9.1万桶。但与去年同期的每日14.1万桶相比,出口量也有所下降。 美国国内乙醇产量环比下降至每日101万桶,低于一周前和去年同期的每日104万桶。 因此,美国乙醇库存从前一周的2690万桶降至2590万桶。不过,这一水平仍高于去年同期的2540万桶。

Related Articles

Research

Research Alert: The Clorox Company Beats Estimates Driven By Household And International

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CLX reported Q3 FY 26 net sales of $1.67B, flat Y/Y with organic sales down 1%, while adj. EPS of $1.64 grew 13% and beat consensus by $0.10. Gross margin contracted 140 bps to 43.2% due to elevated manufacturing costs and unfavorable mix, though disciplined expense management supported earnings. Mixed segment performance showed Household and International delivering growth of 3% and 8%, respectively, while Lifestyle declined 9% on lower consumption and inventory adjustments. Management updated FY 26 guidance expecting net sales to decline ~6% with organic sales down ~9%, including a 7.5%-pt ERP headwind. Adj. EPS guidance of $5.45-$5.65 represents a 27%-29% decline, with gross margin expected to contract 250-300 bps from GOJO inventory step-up and elevated energy costs. The April 1 GOJO acquisition expands the health portfolio though near-term integration costs pressure results. We believe the completed $580M digital transformation positions CLX for long-term operational improvements despite macro headwinds.

$CLX
Research

Research Alert: Rivn: Q1 Eps Ahead Of Consensus; 2026 Guidance Unchanged

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Rivian (RIVN) posted Q1 adjusted EPS of -$0.55 vs. -$0.41, ahead of the -$0.60 consensus. Revenue rose 11% to $1.38B ($10M ahead of consensus) on a 20% increase in total vehicle sales to 10,365 units, augmented by a 49% Y/Y increase in software and services revenue to $473M. RIVN's gross margin contracted 800 bps to 8.6%, but was ahead of the 8.4% consensus. The quarter's financial results reflect the company's strategic pivot toward broader market accessibility with the R2, though at the cost of near-term profitability. RIVN maintained prior 2026 guidance for adjusted EBITDA, vehicle deliveries, and capex. The company ended Q1 with cash of $4.8B, down from $6.1B at year-end 2025. Shares are trading 1% higher in after-hours trading. RIVN's Q1 earnings were ahead of expectations, although cash burn remains a key concern, with free cash flow deteriorating, driven by increased operating expenses and working capital consumption. Execution risks remain high given challenging demand facing the broader EV industry.

$RiVN
Australia

Tanger Q1 Core FFO, Revenue Rise; 2026 Guidance Increased

Tanger (SKT) reported Q1 core funds from operations late Thursday of $0.59 per diluted share, up from $0.53 a year earlier.Analysts polled by FactSet expected $0.58.Revenue in the three months ended March 31 rose to $150.4 million from $135.4 million a year earlier.Analysts surveyed by FactSet expected $142.9 million.The company raised 2026 FFO guidance to $2.42 to $2.50 per diluted share from $2.41 to $2.49.Analysts polled by FactSet expect $2.47.Tanger shares fell 2.3% in after-hours trading.

$SKT